52 citations
,
October 2010 in “Antiviral Therapy” This review discusses recent advances in monophosphate prodrug strategies for HCV drug discovery, aiming to enhance oral absorption and stability, and reports no new clinical results.
October 2011 in “The American Journal of Gastroenterology” This study found that methadone use in HCV-infected male veterans was associated with a significant increase in the risk of advanced liver fibrosis.
May 2019 in “Gastroenterology” Androgen lowering medications don't significantly change HCV-related liver cancer risk in men.
June 2016 in “Afro-Egyptian Journal of Infectious and Endemic Diseases” In this study, 97% of patients undergoing pegylated interferon alfa2a and ribavirin therapy for chronic hepatitis C experienced one or more skin-related side effects, with hair loss being the most common.
4 citations
,
April 2016 in “Journal of The American Academy of Dermatology” This case report details the first known instance of interferon-induced lichen planus in a seronegative HCV patient with metastatic renal cell carcinoma.